Beneficial effects of angiotensin converting enzyme inhibitors (ACEI) and angiotensin type 1
receptor (AT1) blockers in patients with cardiovascular and renal diseases have been …

The development of pharmacologic agents that directly inhibit the angiotensin II receptor
(angiotensin receptor blocker [ARB]) has provided clinicians with an alternative to the …

Due to its hemodynamic, metabolic and growth promoting effects, angiotensin II (AII) may
play an important role in the pathogenesis of diabetic kidney disease. Consequently …

Despite a similar beneficial effect on blood pressure lowering observed with angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor (AT1R) blocker …

In the prevention and treatment of cardiovascular disease, pharmacological treatment
strategies should have several aims:(i) in individuals without overt cardiovascular disease …

This review deals with similarities and differences between the effects of ACE inhibitors and
AT1‐receptor blockers in the kidney. Specific receptor blockade has demonstrated that the …

Background Treatment with angiotensin converting enzyme (ACE) inhibitors reduces
mortality and morbidity among patients with heart failure, left-ventricular dysfunction after …

Angiotensin II is the most active hormone of the reninangiotensin system. In humans, two
angiotensin receptors have been identified: AT 1 and AT 2. In adults, most of the effects of …

Following extensive clinical research, drugs affecting the renin–angiotensin system have
been used for the treatment of patients with congestive heart failure, myocardial infarction …

Background The renin-angiotensin system (RAS) plays a central pathogenic role in the
development of hypertension and associated vascular disorders. However, whether the two …